See more : L.K. Technology Holdings Limited (0558.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Reneo Pharmaceuticals, Inc. (RPHM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reneo Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hefei Kewell Power System Co.,Ltd. (688551.SS) Income Statement Analysis – Financial Results
- Ruichang Intl Hldg Ltd (1334.HK) Income Statement Analysis – Financial Results
- Goldenbridge Acquisition Limited (GBRGU) Income Statement Analysis – Financial Results
- ARTERIA Networks Corporation (4423.T) Income Statement Analysis – Financial Results
- HAMMONIA Schiffsholding AG (HHX.HM) Income Statement Analysis – Financial Results
Reneo Pharmaceuticals, Inc. (RPHM)
About Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 525.00K | 529.00K | 50.00K | 37.00K | 34.00K |
| Gross Profit | -525.00K | -529.00K | -50.00K | -37.00K | -34.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.61M | 37.71M | 28.17M | 15.94M | 13.10M |
| General & Administrative | 25.79M | 16.14M | 11.65M | 3.61M | 2.38M |
| Selling & Marketing | 26.44M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.79M | 16.14M | 11.65M | 3.61M | 2.38M |
| Other Expenses | 650.00K | 1.89M | 48.00K | 87.00K | 3.04M |
| Operating Expenses | 83.05M | 53.85M | 39.82M | 19.55M | 15.47M |
| Cost & Expenses | 83.05M | 53.85M | 39.82M | 19.55M | 15.47M |
| Interest Income | 0.00 | 1.89K | 48.00 | 87.00K | 456.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 170.00K | 529.00K | 50.00K | 37.00K | 34.00K |
| EBITDA | -82.23M | -53.76M | -39.77M | -19.52M | -15.44M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -83.05M | -53.85M | -39.82M | -19.55M | -15.47M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.67M | 1.89M | 48.00K | 87.00K | 3.04M |
| Income Before Tax | -77.39M | -51.96M | -39.77M | -19.47M | -12.44M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 650.00K | -1.89M | -186.56K | -169.30K | -137.86K |
| Net Income | -77.39M | -50.06M | -39.77M | -19.47M | -12.44M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -25.23 | -2.04 | -2.19 | -0.80 | -1.60 |
| EPS Diluted | -25.23 | -2.04 | -2.19 | -0.80 | -1.60 |
| Weighted Avg Shares Out | 3.07M | 24.50M | 18.14M | 24.21M | 7.79M |
| Weighted Avg Shares Out (Dil) | 3.07M | 24.50M | 18.14M | 24.21M | 7.79M |
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer -- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024 -- Post-transaction cash,...
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
– Combined company to trade on Nasdaq under ticker “OKUR” – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) today announced the results of the special meeting of...
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) and OnKure, Inc. is fair to Reneo shareholders. Pre-merger Reneo shareholders are expected to own approximately 31% of the...
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter...
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
NEW YORK , June 24, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of Shareholders
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Reneo Pharmaceuticals, Inc. (NasdaqGM: RPHM) (the “Company”) and OnKure, Inc. Upon...
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Reneo Pharmaceuticals, Inc. - RPHM
NEW YORK , May 13, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
Source: https://incomestatements.info
Category: Stock Reports